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repair has run its course, a cryopreserved valve may help
the patient to function for another few years. In our expe-
rience, failure of the graft with occlusion is not sympto-
matically a problem, and so, even with failure, a few more
years of symptomatic relief can be expected.
Rejection may certainly be a factor in the failure of
these grafts, if the arterial graft literature is applicable.
Immunosuppression, if ever useful, must be at a degree
that would not hinder venus ulcer healing, but would pro-
tect the allograft. Probably some type of Cytotoxic T-cell
immunosuppressive agent will be required. At this time, I
have no data to suggest how this factor may play out in
clinical practice.
Thank you.
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CALL FOR ABSTRACTS
Trainees at the level of student (undergraduate, medical, or graduate school), residents, and
fellows are encouraged to submit abstracts for a poster session to be held during the 2000
Research Initiatives Conference. Selected abstracts will also be considered for publication in
the Journal of Vascular Surgery and the Journal of Vascular and Interventional Radiology, and
all trainees selected to participate in the poster session will receive up to $1000 for travel
expenses to attend the conference. Deadline for receipt of abstracts is October 27, 1999. 
To obtain an abstract transmittal form or further information on attending the Conference,
please contact: The Lifeline Foundation, 13 Elm St, Manchester, MA 01944; 978-526-8330;
fax 978-526-7521; or email lifeline@prri.com.
